Immuneering Corporation
NASDAQ:IMRXBiotechnology
-$0.01 today
- Market cap
- $226.67M
- Beta
- 0.38
- P/E (TTM)
- -3.6
- EPS (TTM)
- -$1.24
Volume 0.73M
Average 1.38M
IMRX Account Payables
Amounts the company owes suppliers for goods and services received.
Immuneering CorporationNASDAQ: IMRX
Account Payables · Q1 FY2026 · quarter ended Mar 2026
Account payables rises 110780.3% from a year ago
Account payables stood at $1.45B at the end of Q1 FY2026, up 110780.3% from a year earlier and up 94093.5% from the prior quarter. Over 3 fiscal years it compounded at -21.2% a year.
Context
- Account payables amounted to 0.7% of total assets at the end of Q1 FY2026, down 1.9 pp from a year earlier.
- Account payables increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether account payables keeps rising in the next quarterly balance sheet after a +110780.3% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Account Payables history
USD · from the balance sheet
- Latest · FY2025
- 1.54M USD
- Year-over-year change
- -21.2%
- 4-year CAGR
- +2.6%
| Period | Period end | Account Payables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 1.54M | -21.2% |
| FY2024 | 2024-12-31 | 1.96M | -7.3% |
| FY2023 | 2023-12-31 | 2.11M | -33.1% |
| FY2022 | 2022-12-31 | 3.15M | +126.2% |
| FY2021 | 2021-12-31 | 1.39M | — |
Account Payables vs competitors
How IMRX compares with its peers on the latest reported figures
- IMRX's Mar 2026 account payables of $1.45B is the highest of the 11 companies compared; the peer median is $3.12M.
- Its year-over-year change of +110780.3% is the highest of 11, against a peer median of +10.4%.
- Account payables amounts to 0.7% of total assets for IMRX, versus a peer median of 1.4%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $1.45B | +110780.3% | -21.2% | 0.7% | |
| Mar 2026 | $5.08M | -8.8% | +50.2% | 4.6% | |
| Mar 2026 | $4.99M | +75.3% | +15.3% | 7.8% | |
| Mar 2026 | $4.36M | -8.3% | -31.3% | 1.4% | |
| Mar 2026 | $4.09M | -33.8% | -17.2% | 1.7% | |
| Mar 2026 | $3.32M | -18.5% | -7.6% | 1.5% | |
| Mar 2026 | $2.93M | +33.9% | -27.4% | 0.9% | |
ZURAZura Bio Limited | Mar 2026 | $2.08M | +66.8% | -14.0% | 0.9% |
| Mar 2026 | $1.91M | -62.2% | -28.0% | 1.4% | |
| Mar 2026 | $1.19M | +41.0% | -9.5% | 0.7% | |
| Mar 2026 | $1.13M | +29.0% | -22.3% | 0.5% | |
| Peer median (excluding IMRX) | $3.12M | +10.4% | -15.6% | 1.4% | |
Competitors are the stored peer set for IMRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 74.89M | 72.64M | 59.41M | 36.14M | 128.65M |
| Short-term Investments | 74.31M | 32.89M | 26.26M | 0 | 44.19M |
| Net Receivables | 246.04K | 12.42K | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 0 | 3.21M | 3.42M | 3.44M | 3.41M |
| Total Current Assets | 152.33M | 108.75M | 89.08M | 39.59M | 176.25M |
| Property, Plant & Equipment (Net) | 6.13M | 5.78M | 5.4M | 4.79M | 4.26M |
| Goodwill | 6.7M | 6.69M | 6.69M | 6.69M | 6.69M |
| Intangible Assets | 439K | 408.95K | 379.68K | 350.41K | 321.15K |
| Long-term Investments | 996.56K | 0 | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 102.13K | 743.7K | 1.03M | 1.3M | 44.47M |
| Total Non-current Assets | 14.37M | 13.62M | 13.5M | 13.13M | 55.74M |
| Total Assets | 166.7M | 122.37M | 102.58M | 52.71M | 231.99M |
| Account Payables | 1.39M | 3.15M | 2.11M | 1.96M | 1.54M |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 2.92M | 3.65M | 3.89M | 3.82M | 4.54M |
| Total Current Liabilities | 5.63M | 8.05M | 7.85M | 7.5M | 10.07M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 0 | 0 | 0 | 0 | 0 |
| Total Non-current Liabilities | 5.09M | 4.46M | 4.16M | 3.82M | 3.43M |
| Total Liabilities | 10.72M | 12.52M | 12.01M | 11.33M | 13.5M |
| Common Stock | 26.32K | 26.42K | 29.27K | 31.05K | 64.65K |
| Retained Earnings | (59.27M) | (109.79M) | (163.26M) | (224.3M) | (280.32M) |
| Accumulated OCI | (49.01K) | (30.12K) | (778) | 0 | 81.33K |
| Other Stockholders Equity | 0 | 0 | 0 | 1 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 155.98M | 109.85M | 90.58M | 41.39M | 218.48M |
| Total Debt | 5.36M | 4.84M | 4.46M | 4.16M | 3.82M |
| Net Debt | (69.52M) | (67.8M) | (54.94M) | (31.98M) | (124.82M) |
Immuneering Corporation
NASDAQ:IMRX
Intrinsic Alpha fair value
Locked
Current Price
$3.50
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.